Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?

This publication has 73 references indexed in Scilit:

• Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma
  Trends in Pharmacological Sciences, 1996
• Agents That Elevate cAMP Inhibit Human Neutrophil Apoptosis
  Biochemical and Biophysical Research Communications, 1995
• Delayed protection of the heart against ischaemia
  Trends in Pharmacological Sciences, 1995
• Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in Brown-Norway rats
  Inflammation Research, 1995
• A novel insulin secretagogue is a phosphodiesterase inhibitor
  Diabetes, 1995
• Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
  International Journal of Immunopharmacology, 1994
• Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis
  Journal of Allergy and Clinical Immunology, 1993
• Apoptosis
  Immunology Today, 1993
• The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response
  Immunology Today, 1988
• The Value of Maintenance Theophylline in Steroid-Dependent Asthma
  New England Journal of Medicine, 1981